Transcripta Bio raised $24 million since its Series A to advance IND-enabling work across its neuro pipeline. The funding supports clinical preparation in autism spectrum disorder and facioscapulohumeral muscular dystrophy, with additional programs for myotonic dystrophy and Huntington’s disease planned to progress through development milestones.